Współczesna Onkologia

Ophthalmic complications associated with chimeric antigen receptor T-cell therapy: a review of current evidence

Joanna Mamczur-Załęcka 1
,
Lidia Gil 2
,
Agata Brązert 1
,
Bartosz Małecki 2
,
Andrzej Szczepaniak 2
,
Jarosław Kocięcki 1

  1. Department of Ophthalmology, Poznan University of Medical Sciences, Poznan, Poland

  2. Department of Haematology, Transplantation and Cellular Therapy, Poznan University of Medical Sciences, Poznan, Poland

Contemp Oncol (Pozn) 2026; 30 (3)

DOI: https://doi.org/10.5114/wo.2026.165736
Data publikacji online: 2026/10/19
Article file
Ophthalmic complications.pdf
  1. Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Sig Transduct Target Ther 2025; 10: 210.
  2. Bock TJ, Colonne CK, Fiorenza S, Turtle CJ. Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma. Nat Rev Clin Oncol 2025; 22: 241-261.
  3. Chen R, Chen L, Wang C, Zhu H, Gu L, Li Y, et al. CAR-T treatment for cancer: prospects and challenges. Front Oncol 2023; 13: 1288383.
  4. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 2021; 11: 69.
  5. Zhang L, Meng Y, Feng X, Han Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res 2022; 10: 12.
  6. Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D. Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input. Cancers 2023; 15: 1003.
  7. Golmohammadi M, Noorbakhsh N, Kavianpour M. CAR-T cell therapy: managing side effects and overcoming challenges. Adv Biomed Res 2025; 14.
  8. Nie EH, Su Y-J, Baird JH, Agarwal N, Bharadwaj S, Weng WK, et al. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma. Blood Adv 2024; 8: 1474-1486.
  9. Frey C, Cherniawsky H, Etminan M. Ocular adverse events following CAR-T cell therapy: a pharmacovigilance study and systematic review. Eur J Haematol 2024; 113: 66-71.
  10. Murty T, Wai KM, Rahimy E, Mruthyunjaya P. Low occurrence of ocular adverse events after CAR-T cell therapy. Ocul Oncol Pathol 2025; 11: 104-108.
  11. Kikuchi T, Watanabe M, Tsukada N, Matsumoto C, Nomura- Yogo M, Kunisada K, et al. Cytomegalovirus retinitis during idecabtagene vicleucel therapy in patients with relapsed/refractory multiple myeloma. Transpl Infect Dis 2025; 27: e70040.
  12. Mumtaz AA, Fischer A, Lutfi F, Matsumoto LR, Atanackovic D, Kolanci ET, et al. Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review. Br J Ophthalmol 2023; 107: 901-905.
  13. Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, et al. Beyond the storm – subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 2021; 18: 363-378.
  14. Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of chimeric receptor composed of immunoglobulin- derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1987; 149: 960-968.
  15. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989; 86: 1333-1337.
  16. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR /CD28 receptor. Nat Biotechnol 2002; 20: 70-75.
  17. Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy 2020; 22: 57-69.
  18. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378: 439-448.
  19. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacob- son CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med 2017; 377: 2531-2544.
  20. U.S. Food and Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome (accessed: 19.04.2026).
  21. U.S. Food and Drug Administration. FDA approves axicabtagene ciloleucel for large B-cell lymphoma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma (accessed: 19.04.2026).
  22. Krause A, Guo HF, Latouche JB, Tan C, Cheung NKV, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998; 188: 619-626.
  23. Brentjens RJ, Latouche J-B, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9: 279-286.
  24. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-724.
  25. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody- type specificity. Proc Natl Acad Sci USA 1989; 86: 10024-10028.
  26. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler- Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099-4102.
  27. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
  28. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5.
  29. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625-638.
  30. Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 2014; 26: 43-49.
  31. Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 2019; 25: e123-e127.
  32. Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol 2024; 21: 501-521.
  33. Ferreri CJ, Bhutani M. Mechanisms and management of CAR T toxicity. Front Oncol 2024; 14: 1396490.
  34. Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021; 384: 705-716.
  35. Mikkilineni L, Natrakul DA, Lam N, Manasanch EE, Mann J, Weis- sler KA, et al. Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain. Mol Ther 2024; 32: 503-526.
  36. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Co- hen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-324.
  37. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassa- day RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021; 398: 491-502.
  38. Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol 2020; 38: 3095-3106.
  39. Rees JH. Management of immune effector cell-associated neurotoxicity syndrome (ICANS). In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (ed.). The EBMT/EHA CAR-T cell handbook. Springer International Publishing, Cham 2022, 141-145.
  40. Schroeder T, Martens T, Fransecky L, Valerius T, Schub N, Pott C, et al. Management of chimeric antigen receptor T (CAR-T) cell- associated toxicities. Intensive Care Med 2024; 50: 1459-1469.
  41. Sharma N, Reagan PM, Liesveld JL. Cytopenia after CAR-T cell therapy – a brief review of a complex problem. Cancers 2022; 14: 1501.
  42. Sarwar S, Riaz U, Ali A, Kailash SJ. Adverse events associated with chimeric antigen receptor T-cell therapy in ophthalmology: a narrative review. Ann Med Surg (Lond) 2024; 86: 4035-4041.
  43. Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 2020; 136: 925-935.
  44. Arya S, Shahid Z. Overview of infectious complications among CAR T- cell therapy recipients. Front Oncol 2024; 14: 1398078.
  45. Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis 2018; 67: 533-540.
  46. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768.
  47. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020; 382: 1331-1342.
  48. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang ML, Arnason JE, et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood 2019; 134: 241-241.
  49. European Medicines Agency. Kymriah (tisagenlecleucel): EPAR. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah (accessed: 13.05.2026).
  50. European Medicines Agency. Yescarta (axicabtagene ciloleucel): EPAR. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta (accessed: 13.05.2026).
  51. Li Z, Zhang T, Fei Q, Wang X, Li J, Tao Y, et al. Case report: CAR-T cell therapy bridging to allogeneic hematopoietic stem cell transplantation triggers Purtscher-like retinopathy: clinical features and complement-mediated microvascular injury mechanisms. Front Immunol 2026; 17: 1670399.
  52. Taher A, Abadir E, McCluskey P, Hamad N, Lo TH, Heydon P. Presumptive recurrence of intra-ocular lymphoma despite chimeric antigen receptor t-cell therapy. Retin Cases Brief Rep 2023; 17: 562-566.
  53. Wang E, Ma Y, Dai R, Zhang M. Cytomegalovirus retinitis mimicking intraocular lymphoma recurrence following combined autologous transplantation and CAR-T cell therapy. Retin Cases Brief Rep 2026.
  54. Alsarhani WK, Abu El-Asrar AM. Varicella zoster viral retinitis following chimeric antigenic response T-cell therapy for B-cell lymphoma. Ocul Immunol Inflamm 2022; 30: 1447-1448.
  55. Khanna S, Mackin AG, Dao DT, Komati R, Morocco PC, LaBelle JL, et al. Exudative retinal detachment following chimeric antigen receptor T-cell therapy in relapsed B-cell acute lymphoblastic leukemia. Ophthalmic Surg Lasers Imaging Retina 2022; 53: 113-115.
  56. Zu C, Xu Y, Wang Y, Zhang M, Zhao H, Fang X, et al. Cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor T cell therapy for relapsed/refractory multiple myeloma. Curr Oncol 2022; 29: 490-496.
  57. Denton CC, Gange WS, Abdel-Azim H, Jodele S, Kapoor N, Ober- ley MJ, et al. Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. Blood Adv 2020; 4: 2158-2162.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications